In silico identification of selective cyclodecapeptide inhibitors targeting Plasmodium falciparum Grp78 chaperone

Wendy Mthembu1, Adeshina Odugbemi1, Florence Lisa Muzenda1

  • 1Department of Biochemistry, Stellenbosch University, Stellenbosch, 7599, South Africa.

Insights

Drug resistance in Plasmodium falciparum malaria is a major challenge. This study identifies cyclodecapeptides that inhibit PfGrp78, a key protein in parasite stress response, offering a new therapeutic strategy.

Area of Science:

  • Biochemistry
  • Parasitology
  • Drug Discovery

Background:

  • Plasmodium falciparum (Pf) drug resistance, particularly to first-line antimalarials, is a significant obstacle in malaria eradication.
  • Parasite resistance is linked to the endoplasmic reticulum (ER) stress response, with ER-resident glucose-regulated protein 78 (PfGrp78) acting as a crucial sensor.
  • Targeting the parasite's ER protein folding system presents a novel therapeutic avenue, yet remains underexplored.

Purpose of the Study:

  • To identify peptides that mimic PfGrp78 substrates, serving as potential inhibitors of PfGrp78.
  • To investigate the mechanism of action of cyclodecapeptides, gramicidin S (GS) and tyrocidines (Trcs), known for their antimalarial activity.

Main Methods:

  • Utilized molecular docking and molecular dynamics simulations to predict binding interactions.
  • Employed extensive thermodynamics simulations to analyze peptide binding stability and inhibitory mechanisms.
  • Focused on the chaperone-substrate relationship to understand cyclodecapeptide action.

Main Results:

  • Cyclodecapeptides were predicted to bind preferentially to the substrate binding domain (β-SBD) of PfGrp78.
  • Specific binding sites involving residues Gly426-Thr446 and Pro455-Val457 were identified.
  • Thermodynamics simulations confirmed stable peptide binding and revealed inhibitory mechanisms, including conformational locking that restricts PfGrp78's chaperone cycle.

Conclusions:

  • Anti-plasmodial cyclodecapeptides, TrcA and GS, are predicted to inhibit PfGrp78 by inducing conformational locking.
  • These compounds show preferential binding to PfGrp78 over its parasite cytosolic isoform and human homologs.
  • The findings provide a basis for further experimental validation of these peptides as potential antimalarial agents targeting ER stress pathways.

Related Concept Videos